MASCT by Hengrui Yuanzheng Biotechnology for Solid Tumor: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Solid Tumor.

Digital Transformation in Healthcare: Why Build vs. Buy Matter

Lee Jones, Chief Product Officer for Gozio Health There has never been more pressure for health systems to invest in digital transformation, especially when it

October 14, 2024

Senators push IRS to launch nonprofit hospital probe

WASHINGTON — A bipartisan group of senators wants federal tax regulators to probe nonprofit hospitals’ compliance with community benefit requirements, ratcheting up a longtime campaign

August 8, 2023

Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and

January 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.